November 25, 2016 - By Hazel Jackson
Jack Jerrett, SVP & General Counsel of Orasure Technologies Inc is the insider, OctaFinance want to write about today. Mr. Jack submitted a legally required report with the Security and Exchange Commission making public a sale for 24,000 shares of the Pennsylvania-based company, the one he is an insider in. At the time of the trade, the average stock price of Orasure Technologies Inc was $9.0, making the shares block worth $216,000 U.S Dollars. Jack Jerrett now owns 48,105 shares or 0.09% of Orasure Technologies Inc’s total market cap.
Out of 5 analysts covering OraSure Technologies (NASDAQ:OSUR), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $10 is the highest target while $8 is the lowest. The $8.67 average target is -2.47% below today’s ($8.89) stock price. OraSure Technologies has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Thursday, November 5, the company rating was maintained by Mizuho. The stock of OraSure Technologies, Inc. (NASDAQ:OSUR) has “Neutral” rating given on Monday, September 19 by BTIG Research. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. The company was downgraded on Monday, June 13 by Raymond James. The rating was maintained by Canaccord Genuity on Wednesday, August 24 with “Buy”.
Insitutional Activity: The institutional sentiment decreased to 1.06 in Q2 2016. Its down 0.46, from 1.52 in 2016Q1. The ratio dived, as 11 funds sold all OraSure Technologies, Inc. shares owned while 39 reduced positions. 25 funds bought stakes while 51 increased positions. They now own 43.86 million shares or 2.62% more from 42.75 million shares in 2016Q1.
Argyle Cap Management Inc owns 35,275 shares or 0.09% of their US portfolio. Shinko Asset Management accumulated 0.03% or 824,592 shares. Moreover, Cubist Systematic Strategies Limited Com has 0.01% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 24,331 shares. Blackrock last reported 3,772 shares in the company. Springbok Cap Mngmt Ltd Limited Liability Company accumulated 0.02% or 22,700 shares. The New Jersey-based Kcg has invested 0.01% in OraSure Technologies, Inc. (NASDAQ:OSUR). Moreover, Stevens Cap L P has 0% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 12,519 shares. Credit Suisse Ag last reported 0% of its portfolio in the stock. Airain Ltd accumulated 23,187 shares or 0.01% of the stock. Bb&T holds 11,053 shares or 0% of its portfolio. Jacobs Levy Equity Mgmt accumulated 41,100 shares or 0.01% of the stock. Gsa Cap Ptnrs Llp holds 0.06% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR) for 188,259 shares. Glenmede Communication Na holds 76,570 shares or 0% of its portfolio. Manatuck Hill Ptnrs Ltd Co holds 0.08% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR) for 30,000 shares. Teacher Retirement Systems Of Texas accumulated 0% or 7,897 shares.
Insider Transactions: Since August 5, 2016, the stock had 0 insider buys, and 3 insider sales for $1.01 million net activity. $217,722 worth of OraSure Technologies, Inc. (NASDAQ:OSUR) shares were sold by Patrick Charles W. On Monday, September 26 Michels Douglas A sold $205,525 worth of the stock or 25,000 shares. 68,686 shares were sold by JERRETT JACK E, worth $585,422 on Tuesday, August 30.
About 176,658 shares traded hands. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 21.67% since April 22, 2016 and is uptrending. It has outperformed by 16.26% the S&P500.
OraSure Technologies, Inc. is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company has a market cap of $493.78 million. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It has a 29.4 P/E ratio. The Company’s diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D.
According to Zacks Investment Research, “OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians’ offices, and workplace sites.”
Analysts await OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings on February, 1. They expect $0.05 earnings per share, down 37.50% or $0.03 from last year’s $0.08 per share. OSUR’s profit will be $2.78M for 44.45 P/E if the $0.05 EPS becomes a reality. After $0.11 actual earnings per share reported by OraSure Technologies, Inc. for the previous quarter, Wall Street now forecasts -54.55% negative EPS growth.
More news for OraSure Technologies, Inc. (NASDAQ:OSUR) were recently published by: Fool.com, which released: “Why OraSure Technologies, Inc Rose Today” on August 29, 2016. Fool.com‘s article titled: “Why OraSure Technologies, Inc is Jumping Today” and published on August 24, 2016 is yet another important article.
OraSure Technologies, Inc. (OraSure), incorporated on May 5, 2000, is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company’s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. It sells over-the-counter (OTC) cryosurgical products to clients in North America, Europe, Central and South America, and Australia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.